(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sclerosing cholangitis or PSC. The company said the result support the potential for Volixibat as the first treatment for
(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM), Monday said that its VISTAS Phase 2b study evaluating Volixibat met primary endpoint in patients with primary sclerosing cholangitis or PSC. The company said the result support the potential for Volixibat as the first treatment for
Hong Kong recorded a 4.8 per cent increase in mainland Chinese visitors in the first three days of the Labour Day “Golden Week” holiday, but industry players warned that uneven spending and more flexible travel patterns could weigh on business despite hotel occupancy rates potentially reaching 90 per cent. Immigration Department data showed mainlanders made 714,765 visits into the city between May...
Hong Kong recorded a 4.8 per cent increase in mainland Chinese visitors in the first three days of the Labour Day “Golden Week” holiday, but industry players warned that uneven spending and more flexible travel patterns could weigh on business despite hotel occupancy rates potentially reaching 90 per cent. Immigration Department data showed mainlanders made 714,765 visits into the city between May 1 and 3, up by about 4.8 per cent from 682,114 in the same period last year. Total visitor...
Investing.com -- HSBC on Monday downgraded Advanced Micro Devices to Hold from Buy, raising its price target slightly to $340 from $335, as the bank sees little room for the chipmaker to meaningfully beat market expectations despite strong demand for its server processors.
Investing.com -- HSBC on Monday downgraded Advanced Micro Devices to Hold from Buy, raising its price target slightly to $340 from $335, as the bank sees little room for the chipmaker to meaningfully beat market expectations despite strong demand for its server processors.
Many financial stocks are quiet, solid powerhouses that don't get a lot of attention but offer fabulous opportunities. Consider Fair Isaac (NYSE: FICO) , the leading credit evaluation company. You might know it because of the ubiquitous FICO score that often determines your creditworthiness, but behind the score is a financial giant that's been a pretty reliable market-beater until recently. Let's...
Many financial stocks are quiet, solid powerhouses that don't get a lot of attention but offer fabulous opportunities. Consider Fair Isaac (NYSE: FICO) , the leading credit evaluation company. You might know it because of the ubiquitous FICO score that often determines your creditworthiness, but behind the score is a financial giant that's been a pretty reliable market-beater until recently. Let's see why Fair Isaac has a fantastic business, why it's down right now, and whether or not it's a bargain at the current price. Continue reading
Bill Ackman's Pershing Square (NYSE: PS) made its U.S. market debut with the IPO of a new closed-end fund, Pershing Square USA (NYSE: PSUS) . The hedge fund manager successfully raised $5 billion for the new fund, offering shares in the management company as an incentive for IPO subscribers. Ackman's firm also manages another closed-end fund, Pershing Square Holdings (LSE: PSH) , which is traded i...
Bill Ackman's Pershing Square (NYSE: PS) made its U.S. market debut with the IPO of a new closed-end fund, Pershing Square USA (NYSE: PSUS) . The hedge fund manager successfully raised $5 billion for the new fund, offering shares in the management company as an incentive for IPO subscribers. Ackman's firm also manages another closed-end fund, Pershing Square Holdings (LSE: PSH) , which is traded in Europe, as well as Howard Hughes Holdings . But the new listing is the most straightforward path for Americans to invest directly in the same stocks as Bill Ackman . There's good reason to be interested. Ackman's investments have produced annualized returns of 16.2% since he founded his limited partnership in 2004. But there's an even better option for most investors than buying into the new U.S.-listed fund. Continue reading
Asbury Automotive on Monday said David Hult has formally transitioned from CEO to executive chairman, effective immediately, marking a leadership shift after a period of significant expansion for the dealership operator. More on Asbury Automotive Asbury Automotive Group, Inc. (ABG) Q1 2026 Earnings Call Transcript Asbury Automotive Group, Inc. 2026 Q1 - Results - Earnings Call Presentation Asbury ...
Asbury Automotive on Monday said David Hult has formally transitioned from CEO to executive chairman, effective immediately, marking a leadership shift after a period of significant expansion for the dealership operator. More on Asbury Automotive Asbury Automotive Group, Inc. (ABG) Q1 2026 Earnings Call Transcript Asbury Automotive Group, Inc. 2026 Q1 - Results - Earnings Call Presentation Asbury Automotive: Aiming At Margin Instead Of Volume Asbury outlines full Tekion conversion by fall 2026 while maintaining about $250M in 2026 CapEx Asbury Automotive Non-GAAP EPS of $5.37 misses by $0.25, revenue of $4.1B misses by $270M
In this article @LCO.1 @CL.1 Follow your favorite stocks CREATE FREE ACCOUNT Global economies could be "sleepwalking" into a "big recession", as investors continue to underplay the impact of the oil price shock, Amrita Sen, founder and director, market intelligence at Energy Aspect, told CNBC's "Squawk Box Europe" on Monday. The S&P 500 hit a new all-time intraday high last week, with the broad ma...
In this article @LCO.1 @CL.1 Follow your favorite stocks CREATE FREE ACCOUNT Global economies could be "sleepwalking" into a "big recession", as investors continue to underplay the impact of the oil price shock, Amrita Sen, founder and director, market intelligence at Energy Aspect, told CNBC's "Squawk Box Europe" on Monday. The S&P 500 hit a new all-time intraday high last week, with the broad market index touching 7,230.12 on May 1. That's despite a surge in the cost of energy caused by the war in the Middle East — with oil prices soaring more than 50% since the U.S.-Iran conflict began on Feb. 28. "This has been the biggest conundrum for us — if anything, we think oil should be higher and the equity market should be a lot, lot weaker," Sen said. "I think we're sleepwalking into potentially a pretty big recession." watch now VIDEO 5:14 05:14 Amrita Sen: Prices in the west have not risen enough Squawk Box Europe Sen said there is an "extremely misplaced euphoria" among many investors, who she believes are continuing to dismiss the ongoing energy squeeze as an issue affecting mainly Asian economies. OPEC has pledged to ramp up its oil production, though Sen cautioned that this increase remains largely symbolic and falls short of what is needed to replace lost supply. 'Massive energy crisis' "The story is really when Hormuz reopens, and at what capacity and what pace it reopens," she noted. "If you assume that the Strait remains disrupted for a longer period of time, you are saying that we all need to go back to 2013 demand levels, about 10 million barrels per day less… we've added a billion more people. I think that's the challenge we have right now — we need oil prices to go up so that we can get the demand reduction." Stock Chart Icon Stock chart icon Brent crude. Looking ahead, Sen said she expects $80-90 a barrel to be the new floor going forward, adding that higher-for-longer prices will reverberate across commodity markets, highlighting the impact on LNG, chem...
Competition for Palantir Technologies is heating up as artificial intelligence agents erode barriers to entry in its software space, according to HSBC, and that could hurt the stock. The investment bank downgraded its rating on Palantir to hold from buy, and cut its price target to $151 from $205, implying just 5% potential upside over the coming year compared with Friday's close. Palantir gained ...
Competition for Palantir Technologies is heating up as artificial intelligence agents erode barriers to entry in its software space, according to HSBC, and that could hurt the stock. The investment bank downgraded its rating on Palantir to hold from buy, and cut its price target to $151 from $205, implying just 5% potential upside over the coming year compared with Friday's close. Palantir gained success by embedding its engineers with customers to implement software and efficiently use the company's AI platform, HSBC analyst Stephen Bersey said in a report published Friday. But that strategy is starting to look less appealing to customers now, he wrote. "The success is inviting similar approaches by competitors like OpenAI," HSBC said. "Moreover, with the proliferation of agentic frameworks and model context protocol (MCP) servers, we think the company's traditional barriers to entry are starting to erode. Though the AI orchestration market is expanding quickly, the prospect of other players gaining share may put downward pressure on Palantir's multiple." For example, Anthropic's growing revenues are shrinking Palantir's, Bersey said. Announcements from Anthropic on various models this year have hit software stocks because of fears AI will disrupt the sector's business model. Palantir is set to report earnings after the market closes Monday. Bersey noted that last quarter's "exceptional" results weren't met by a rally in the share price, adding to his concern for downside risk in the stock. PLTR YTD mountain Palantir in 2026
MacroGenics ( NASDAQ: MGNX ) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners tied to global sales of its drug ZYNYZ. MacroGenics said it will receive $60 million upfront and could get up to $20 million in additional sales-based milestone payments in 2026 under the amended agreement. The deal grants Sagard a capped royalty interest in future...
MacroGenics ( NASDAQ: MGNX ) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners tied to global sales of its drug ZYNYZ. MacroGenics said it will receive $60 million upfront and could get up to $20 million in additional sales-based milestone payments in 2026 under the amended agreement. The deal grants Sagard a capped royalty interest in future global net sales of ZYNYZ, with rights reverting to MacroGenics once Sagard receives up to 1.7 times its investment by September 2032, or 2.0 times thereafter. ZYNYZ, a PD-1 inhibitor, was originally developed by MacroGenics and licensed to Incyte Corporation under a global collaboration agreement. Source: Press Release More on MacroGenics MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript MacroGenics gains removal of FDA partial hold on lead program Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant Seeking Alpha’s Quant Rating on MacroGenics
Broadcom (NASDAQ: AVGO) has become one of the hidden winners in AI infrastructure. The bull case is getting stronger as revenue, margins, and contract visibility improve, but the stock's huge rally means investors need to weigh the upside against a valuation that already prices i
Broadcom (NASDAQ: AVGO) has become one of the hidden winners in AI infrastructure. The bull case is getting stronger as revenue, margins, and contract visibility improve, but the stock's huge rally means investors need to weigh the upside against a valuation that already prices i
(RTTNews) - Following the strength seen during last Friday's session, stocks may show a lack of direction in early trading on Monday. The major index futures are currently pointing to a roughly flat open for the markets, with the S&P 500 futures down by less than a tenth of a per
(RTTNews) - Following the strength seen during last Friday's session, stocks may show a lack of direction in early trading on Monday. The major index futures are currently pointing to a roughly flat open for the markets, with the S&P 500 futures down by less than a tenth of a per
According to a recent SEC filing , Ruedi Wealth Management, Inc. increased its stake in the Dimensional Global Core Plus Fixed Income ETF (NASDAQ:DFGP) by 74,122 shares during the first quarter of 2026. The estimated trade value was $4.0 million, calculated using the average closing price for the quarter. The fund's quarter-end position value rose by $3.9 million -- a figure that reflects both thi...
According to a recent SEC filing , Ruedi Wealth Management, Inc. increased its stake in the Dimensional Global Core Plus Fixed Income ETF (NASDAQ:DFGP) by 74,122 shares during the first quarter of 2026. The estimated trade value was $4.0 million, calculated using the average closing price for the quarter. The fund's quarter-end position value rose by $3.9 million -- a figure that reflects both this purchase and market price changes. Dimensional Global Core Plus Fixed Income ETF (DFGP) is a broadly diversified bond fund that targets both U.S. and international fixed income markets through a systematic, research-driven approach. Ruedi Wealth's continued accumulation of DFGP -- now its second-largest position -- signals more than routine portfolio upkeep. The firm is clearly making a deliberate bet on broadly diversified, low-cost fixed income, and adding to an existing bond allocation of this size suggests genuine conviction. Continue reading
Caldwell Partners International Inc. ( CWLPF ) will repurchase up to 2M common shares, representing 10% of the public float. The 2026 bid will run from May 6, 2026, to May 5, 2027, unless earlier completed or terminated by the company. More on The Caldwell Partners International Inc. Dividend scorecard for The Caldwell Partners International Inc. Financial information for The Caldwell Partners Int...
Caldwell Partners International Inc. ( CWLPF ) will repurchase up to 2M common shares, representing 10% of the public float. The 2026 bid will run from May 6, 2026, to May 5, 2027, unless earlier completed or terminated by the company. More on The Caldwell Partners International Inc. Dividend scorecard for The Caldwell Partners International Inc. Financial information for The Caldwell Partners International Inc.
Sundry Photography GlobalFoundries ( GFS ) was in the spotlight on Monday as Cantor Fitzgerald upgraded the semiconductor foundry ahead of its analyst day, set to be held on May 7. Shares rose 8.3% in premarket trading. Analyst C.J. Muse raised his rating on GlobalFoundries to Overweight from Neutral on the belief that the company is benefiting from multiple drivers, including silicon photonics, s...
Sundry Photography GlobalFoundries ( GFS ) was in the spotlight on Monday as Cantor Fitzgerald upgraded the semiconductor foundry ahead of its analyst day, set to be held on May 7. Shares rose 8.3% in premarket trading. Analyst C.J. Muse raised his rating on GlobalFoundries to Overweight from Neutral on the belief that the company is benefiting from multiple drivers, including silicon photonics, satellite communications, and eventually physical artificial intelligence. “While GF’s targeted $1B in CY28 SiPho revenues may be aggressive given a more challenged technology position vs. TSEM and TSMC, we believe that at minimum the PIC business is strong, and even if GF captures a smaller slice of the overall SiPho pie, it’s setting up to be a significant SAM,” Muse wrote in a note to clients. “Other attractive end-markets include SatCOM & Automotive as well as a strong Industrial technology portfolio that should see momentum as edge computing expands.” Additionally, Muse, who also upped his price target on GlobalFoundries to $80 from $50, said he believes the company may see an inflection point in gross margins, as utilization improves and it moves into accretive markets. “Finally, with 12nm and above capacity starting to tighten, we do see the opportunity for incremental ASP upside (not to the same extent as UMC, but a marginal positive),” Muse added. “Put it all together, and we look for GF to provide a target model in-step with the midpoint to high-end of our 2030 target model with EPS of $4.50-5.50 and where we highlight a 'downside case' of $3.50.” Separately, on Monday, Morgan Stanley raised its price target on GlobalFoundries to $58 from $47. The company also announced its SCALE optical module solution for co-packaged optics. GF said that its silicon photonics co-packaged advanced light engine, or SCALE, solution, is “the industry’s first Optical Compute Interconnect Multi-Source Agreement capable platform, exceeding the requirements for the OCI MSA’s optical inte...
photoschmidt/iStock via Getty Images Today, I am going to eat some humble pie and present to you my biggest losers ever, with the worst one of them, losing 97.7% of my capital. Some of these losses are the result of my own mistakes. Some others are simply the result of risk factors playing out. I take risks to earn returns, and at times, it is inevitable for anyone to face losses as risks material...
photoschmidt/iStock via Getty Images Today, I am going to eat some humble pie and present to you my biggest losers ever, with the worst one of them, losing 97.7% of my capital. Some of these losses are the result of my own mistakes. Some others are simply the result of risk factors playing out. I take risks to earn returns, and at times, it is inevitable for anyone to face losses as risks materialize. There is no free lunch in investing. Since I follow an aggressive investment strategy, seeking to maximize total returns, mostly focusing on the real estate category ( VNQ ), I will often end up investing in companies that are heavily discounted due to overleverage or the ownership of troubled assets. When these companies manage to fix issues, they may regain a higher valuation, resulting in huge upside. As an example, the mall REIT Macerich ( MAC ) used to be overleveraged and suffered from the growth of e-commerce. But as it better diversified its malls and paid off some debt, its stock more than quadrupled in recent years. Our average cost basis in Macerich is just $8, and we have earned lots of dividend income along the way: Data by YCharts But not all of these investments work out as expected, and that's going to be the focus today. Here are 3 of my biggest losses ever, starting with the greatest: Invesque ( IVQ.U:CA / MHIVF ): -97.7% I first invested in Invesque before the pandemic, and the investment thesis was quite simple. Back then, most senior housing REITs like Welltower ( WELL ) and Ventas ( VTR ) traded at fairly expensive multiples. However, Invesque was offered at a steep discount relative to its peers, despite owning a great portfolio of mostly newly built senior housing communities that enjoyed attractive long-term growth prospects. Invesque But there was, of course, a reason for the discount. The company was heavily leveraged with an LTV near 60%, leaving little room for error. Even then, we felt that the risk-to-reward was compelling given that the ...